Lovely compilation of info, CCB. The take home message is that mild/moderate can turn awful almost overnight. Seeing all these papers bearing the same message forcefully pounds in the message that things turn bad in a hurry when the immune response goes haywire. The point of leronlimab is to short-circuit that haywire response, and prevent progression to severe/critical. And there's good reason to think it works.

For the trials, the questions now are how often these events happen (5%, 10%, 20%?), will leronlimab prevent disease progression (seems like it should), and what will the final enrollment number be? If it's 5-10% and n = 50, statistical significance might not be there. If it's 10-20% and n = 75, we could very well see NP's beautiful results that will "shock the world".